Accession Number: | 0001209191-16-138706 |
Date: | 2016-08-23 |
Issuer: | GENOMIC HEALTH INC (GHDX) |
Original Submission Date: |
SHAK STEVEN
301 PENOBSCOT DRIVE
REDWOOD CITY, CA 94063
Title of Security | Transaction Date | 2a. Deemed Execution Date | Transaction Code | Shares | Acquired or Disposed | Price per share | 5. Amount of Securities Beneficially Owned Following Reported Transaction | 6. Ownership Form Direct or Indirect | Nature of Indirect Ownership |
---|---|---|---|---|---|---|---|---|---|
COMMON STOCK | 2016-08-23 | M | 5,000 | a | $18.89 | 332,207 | direct | ||
COMMON STOCK | 2016-08-23 | S | 5,000 | d | $27.24 | 327,207 | direct |
Title of Derivative Security | Conversion or Exercise Price of Derivative Security | Transaction Date | Deemed Execution Date | Transaction Code | Number of Derivative Securities Acquired (A) or Disposed of (D) | Date Exercisable | Expiration Date | Title and Amount of Securities Underlying Derivative Security | Price of Derivative Security | Number of derivative Securities Beneficially Owned Following Reported Transaction(s) | Ownership Form: Direct (D) or Indirect (I) | Nature of Indirect Beneficial Ownership |
---|---|---|---|---|---|---|---|---|---|---|---|---|
EMPLOYEE STOCK OPTION (RIGHT TO BUY) | 18.89 | 2016-08-23 | deemed execution date | M | 5,000 (d) | 2016-11-30 | common stock 5,000 | $18.89 | 15,000 | direct |
ID | footnote |
---|---|
f1 | these sales of common stock were effected pursuant to rule 10b5-1 sales plan adopted by the reporting person on march 1, 2016. |
f2 | represents weighted average sale price. actual sale prices ranged from $26.76 to $27.50. |
f3 | reporting person undertakes to provide upon request by the securities and exchange commission, the issuer or a securityholder of the issuer detailed information regarding the price and number of shares sold within the range indicated. |
f4 | includes an aggregate of 15,764 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. |
f5 | the option became exercisable as to 25% of the shares on november 30, 2007, and became exercisable as to 1/48th of the shares each full month thereafter. |